| Original language | English (US) |
|---|---|
| Pages (from-to) | 1364-1405 |
| Number of pages | 42 |
| Journal | Journal of the American College of Cardiology |
| Volume | 54 |
| Issue number | 14 |
| DOIs | |
| State | Published - Sep 29 2009 |
Funding
American College of Cardiology Foundation John C. Lewin, MD, Chief Executive Officer Charlene May, Senior Director, Science and Clinical Policy Melanie Shahriary, RN, BSN, Associate Director, Performance Measures and Data Standards Kay Conley, RN, MSN, BC, Senior Specialist, Performance Measures Erin A. Barrett, Senior Specialist, Science and Clinical Policy American Heart Association Nancy Brown, Chief Executive Officer Rose Marie Robertson, MD, FAHA, FACC, FESC, Chief Science Officer Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations Kathryn A. Taubert, PhD, FAHA, Senior Scientist Appendix A Author Relationships With Industry and Other Entities—ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults Name Research Grant Speakers' Bureau/Honoraria/ Expert Witness Stock Ownership/ Equity Interests Consultant/ Advisory Board/ Steering Committee Institutional, Organizational or Other Financial Benefit Dr Rita F. Redberg None None None None None Dr Emelia J. Benjamin None None None None None Dr Vera Bittner • Atherogenics * None None • CV Therapeutics None • CV Therapeutics * • Novartis • Merck * • Pfizer • NIH/Abbott joint effort * • Reliant Pharmaceuticals • Pfizer * • Roche * Dr Lynne T. Braun None • AstraZeneca None None None • diaDexus Dr David C. Goff, Jr • Merck * • Scientific Evidence, Inc * None None • Pfizer • St Jude Medical Dr Stephen Havas None None None None None Dr Darwin R. Labarthe None None None None None Dr Marian C. Limacher • Orexigen Therapeutics * None None None None Dr Donald M. Lloyd-Jones None • Abbott None None None • Merck • Pfizer Dr Samia Mora • AstraZeneca * • Pfizer None None None • Merck * Dr Thomas A. Pearson • Sanofi-aventis • Bayer * None None None • Johnson & Johnson/Merck • Kos Pharmaceuticals • Merck/Schering-Plough • Pfizer • Sanofi-aventis Dr Martha J. Radford None None None None None Dr Gerald W. Smetana None None • SafeMed • Harvard Medical International/Novartis None • Pharma Schweiz CME course director Dr John A. Spertus • Amgen * None • CV Outcomes, Inc None None • BMS/Sanofi- aventis Partnership * • Health Outcomes Sciences, LLC • KCCQ (copyright) * • Lilly * • Outcomes Instruments, LLC * • PAQ (copyright) * • PRISM Technology • SAQ (copyright) * Dr Erica W. Swegler None • Abbott None None None CME indicates continuing medical education; KCCQ, Kansas City Cardiomyopathy Questionnaire; NIH, National Institutes of Health; PAQ, personal assessment questionnaire; and SAQ, Seattle Angina Questionnaire. This table represents the relationships of committee members with industry and other entities that were reported by the authors as relevant to this topic during the document development process. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. * Significant (greater than $10 000) relationship. Appendix B Peer Reviewer Relationships With Industry and Other Entities—ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults Name Representation Research Grant Speakers' Bureau/Honoraria/ Expert Witness Stock Ownership/ Equity Interests Consultant/ Advisory Board/ Steering Committee Institutional, Organizational, or Other Financial Benefit Dr Gerald Fletcher Official reviewer—AHA None None None None None Dr Lee Green Official reviewer— ACCF/AHA Task Force on Performance Measures: Lead reviewer None None None None None Dr Laura Hayman Official reviewer—AHA None None None None None Dr Chittur A. Sivaram Official reviewer—ACCF Board of Governors None • ATS * None None None Dr Janet Wright Official reviewer—ACCF Board of Trustees None None None None None Dr Roger Blumenthal Content reviewer— ACCF Prevention of Cardiovascular Disease Committee • General Electric (fellowship support) None None None None Dr C. Annette DuBard Content reviewer— individual None None None None None Dr JoAnne M. Foody Content reviewer— individual None • Johnson & Johnson None None None • Merck • Novartis • Pfizer Dr Patrick McBride Content reviewer—ACCF Prevention of Cardiovascular Disease Committee None • Reliant None None None • Sanofi-aventis ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; and AHA, American Heart Association. This table represents the relationships of peer reviewers with industry and other entities that were reported as relevant to this topic during the document development process. It does not necessarily reflect relationships at the time of publication. Names are listed in alphabetical order within each category of review. Participation in the peer review process does not imply endorsement of this document. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. * Significant (greater than $10 000) relationship. Appendix C Appendix D Appendix E Appendix F CHD score sheet for men using total cholesterol or LDL-C categories. Uses age, total cholesterol (or LDL-C), HDL-C, blood pressure, diabetes, and smoking. Estimates risk for CHD over a period of 10 years based on Framingham experience in men 30 to 74 years of age at baseline. Average risk estimates are based on typical Framingham subjects, and estimates of idealized risk are based on optimal blood pressure, total cholesterol 160 to 199 mg/dL (or LDL-C 100 to 129 mg/dL), HDL-C of 45 mg/dL in men, no diabetes, and no smoking. Use of the LDL-C categories is appropriate when fasting LDL-C measurements are available. Risk estimates were derived from the experience of the Framingham Heart Study, a predominantly white population in Massachusetts. CHD indicates cardiovascular heart diease; chol, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and Pts, patients. Adapted from Wilson et al (50), with permission from Lippincott Williams & Wilkins. Copyright 1998, American Heart Association. *Hard CHD events exclude angina pectoris. **Low risk was calculated for a person the same age, optimal blood pressure, LDL-C 100–129 mg/dL or cholesterol 160–199 mg/dL. HDL-C 45 mg/dL for men or 55 mg/dL for women, nonsmoker, no diabetes. Appendix G Appendix H
Keywords
- ACCF/AHA Performance Measures
- cardiovascular disease
- prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
